Integrated Diagnostics for Prostate Cancer

Información del proyecto

ID-PROSTATE

Identificador del acuerdo de subvención: 961205

DOI

10.3030/961205

Proyecto finalizado el 18 Febrero 2022

Fecha de la firma de la CE 14 Julio 2020

Fecha de inicio 1 Julio 2020

Fecha de finalización 30 Junio 2022

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 3 000 531,25

Aportación de la UE

€ 2 100 371,88

Coordinado por

QUANTIB BV
Netherlands

Periodic Reporting for period 2 - ID-PROSTATE (Integrated Diagnostics for Prostate Cancer)

Período documentado: 2021-07-01 hasta 2022-06-30

Resumen del contexto y de los objetivos generales del proyecto

Prostate cancer is the most common type of cancer in men and their second leading cause of death; however, it is highly treatable in the early stages. Recent studies and clinical trials have demonstrated the efficiency of prostate MRI in early diagnosis, with 5 times less missed cancer cases and 25 % fewer biopsies. Care standards now recommend MRI prior to every biopsy, leading to an increased demand for prostate MRI scans. Conventional radiology reading capacity cannot keep pace with the demand. Quantib BV (Netherlands) developed an AI-enhanced integrated diagnostic solution for the detection of potential tumors and workflow optimization involving urologists, radiologists and pathologists. The current EU-funded ID-PROSTATE project allows further improvement and acceleration focusing on product commercialization.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

An initial version of Quantib Prostate was completed and certified for clinical use in both the United States (FDA clearance) as well as within the EU (CE-certification). This initial version is in use across a network of sites leading to workflow / UX improvements being released rapidly. In addition this initial version has provided critical insight into the needs for the expanded version featuring additional AI-components which has now also been submitted for review to the FDA.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

We expect the expanded version will deliver the ability for clinicians to report on prostate MR at speed beyond the current state-of-the-art. This will impact the adoption and high-quality and cost-effective use of MRI in early diagnosis of prostate cancer and will thus impact men across Europe and the United States.

banner-logo-psa-not-filled.png